2023 2023 Nucleosides, Nucleotides and Oligonucleotides GRC & GRS

2023 2023 核苷、核苷酸和寡核苷酸 GRC

• 批准号: 10609239
• 负责人: Katherine L Seley-Radtke
• 金额: $ 0.7万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-10 至 2023-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10609239
• 关键词: 2019-nCoV; Acute; Address; African American; Antibiotics; Antiviral Agents; Attitude; Basic Science; Biology; Biomedical Research; COVID-19 pandemic; Calibration; Chemicals; Chemistry; Clinic; Collaborations; Communicable Diseases; Communities; Coronavirus; Creativeness; Dedications; Development; Diagnostic; Disease; Effectiveness; Employment Opportunities; Environment; Ethnic Origin; Ethnic Population; Fees; Female; Funding; Funding Agency; Future; Gender; Genetic Diseases; Goals; Government; HIV/AIDS; Health; Hepatitis C; Hour; Human; Human Biology; Industrialization; Industry; Institution; International; Knowledge; Learning; Light; Marketing; Mentors; Minority; Nucleic Acids; Nucleosides; Nucleotides; Occupations; Oligonucleotides; Oral; Organizational Objectives; Participant; Pharmaceutical Preparations; Postdoctoral Fellow; Purine Nucleosides; RNA; Recording of previous events; Research; Research Personnel; Science; Scientist; Spinal Muscular Atrophy; Structural Chemistry; Students; Tenofovir; Therapeutic; Underrepresented Minority; Underrepresented Populations; Woman; Zidovudine; career; clinical application; clinical translation; coronavirus therapeutics; current pandemic; drug development; drug discovery; effective therapy; epitranscriptome; improved; insight; interest; meetings; member; men; new technology; nucleic acid-based therapeutics; posters; programs; recruit; remdesivir; small molecule; social group; success; symposium; tool; undergraduate student; vaccine development

PROJECT SUMMARY/ABSTRACT This proposal seeks funding to support the 2023 Nucleosides, Nucleotides and Oligonucleotides (NNO) Gordon Research Conference and associated Gordon Research Seminar. This will be the 21st edition of this conference, which was initiated in 1976. Throughout its history, this conference has addressed topics that are directly related to the fundamental science of human biology and the treatment of disease. Nucleosides and nucleotides have been extremely effective drugs, most notably antivirals such as AZT and Harvoni, for the treatment of HIV/AIDS and hepatitis C, respectively. Meanwhile, the field has broadened to include oligonucleotides as biomedical research tools and, increasingly, therapeutics for genetic diseases, such as Spinraza, which treats spinal muscular atrophy. There are four specific aims for the conference: (1) facilitate scientists in the field to learn about the latest advances in academic, industrial and government research labs; (2) introduce new scientists to the topic; (3) provide networking opportunities to build relationships and collaborations as well as matching students with potential future employers; (4) enhance the diversity of our field by providing speaking and discussion leader opportunities to women and members of under-represented ethnic groups. These specific aims will contribute to long-term goal of the conference, which is to have a broad and sustainable impact on both basic science and clinical translation of nucleosides, nucleotides and oligonucleotides in order to improve human health. The 2023 edition of the conference will include sessions dedicated to (1) emerging therapeutics for coronaviruses, (2) small molecules - chemistry & applications, (3) chemical biology and nucleic acid based diagnostics, (4) oligonucleotide and nucleic acid therapeutics, (5) structural chemistry of nucleic acids, and (6) RNA-targeting and epitranscriptomes. (Other sessions will be organized after final invitations have been accepted and speakers have submitted their titles.) The PI solicited nominations from experts in the field, emphasizing the desire to identify members of under-represented groups and young scientists as potential speakers. Of the 31 invited speakers, 15 are women, including three African-American females; the average GRC has 30% female speakers. In addition, currently we have six speakers from underrepresented minorties. The affiliated Gordon Research Seminar will feature oral presentations by students and postdocs, a panel discussion with established scientists in the field, and the opportunity to create a sense of community prior to the start of the GRC. In addition, the GRC “Power Hour” will take place during one afternoon and provides a forum in which all participants can discuss the unique challenges faced by women in science. Thus, while the cutting edge science described during the oral sessions will undoubtedly inspire others to move their own research forward in new and creative ways, the GRS, Power Hour and other efforts to support women, minorities and young scientists in general will strengthen the field and its impact on human health for decades to come.

项目摘要/摘要 该提案寻求资金支持2023核苷，核苷和寡核苷酸（NNO）Gordon 研究会议和相关的戈登研究研讨会。这将是本次会议的第21版， 该会议于1976年启动。该会议已经解决了直接相关的主题 对人类生物学的基本科学和疾病的治疗。核苷和核苷具有 是极有效的药物，最著名的是抗病毒药，例如AZT和Harvoni，用于治疗HIV/AIDS 和丙型肝炎。同样，该领域已扩大到将寡核苷酸作为生物医学中 研究工具以及越来越多的遗传疾病治疗，例如Spinraza，它治疗脊柱 肌肉萎缩。 会议有四个特定的目标：（1）该领域最喜欢的科学家了解最新 学术，工业和政府研究实验室的进步； （2）向新科学家介绍该主题； （3） 提供建立关系和协作的网络机会，以及使学生与 潜在的未来员工； （4）通过提供演讲和讨论负责人来增强我们领域的多样性 妇女和代表性不足的族裔成员的机会。这些具体目标将有助于 会议的长期目标，即对基础科学和 核外侧，核外侧和寡核苷酸的临床翻译，以改善人类健康。 2023年的会议将包括致力于（1）新兴疗法的会议 冠状病毒，（2）小分子 - 化学与应用，（3）化学生物学和核酸基化学 诊断，（4）寡核苷酸和核酸治疗，（5）核酸的结构化学，（6） RNA靶向和表面分类组。 （在最终邀请后将组织其他会议 被接受和发言人提交了他们的头衔。）PI巩固该领域专家的提名， 强调希望将代表性不足的群体和年轻科学家确定为潜力的愿望 演讲者。在31位受邀演讲者中，有15位女性，其中包括三名非裔美国女性；平均值 GRC有30％的女性演讲者。此外，目前，我们有六位来自代表性不足的杂项的发言人。 会员戈登研究研讨会将由学生和博士后的口头演讲，一个小组 与该领域的既定科学家进行讨论，并有机会在 开始GRC。此外，GRC“电力时光”将在一个下午进行，并提供一个论坛 在其中所有参与者都可以讨论妇女在科学领域面临的独特挑战。那，削减 口头课程中描述的边缘科学无疑会激发他人移动自己的研究 以新的和创造性的方式向前迈向支持妇女，少数民族和其他努力 一般而言，年轻的科学家将在未来几十年中加强该领域及其对人类健康的影响。